Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: Subgroup analysis from RAINBOW study

Ferdinando De Vita*, Christophe Borg, Gabriella Farina, Ravit Geva, Iris Carton, Hera Cuku, Ran Wei, Kei Muro

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: This subgroup analysis of the RAINBOW study evaluated the efficacy and safety of ramucirumab in patients with gastric cancer/gastroesophageal junction adenocarcinoma who received prior trastuzumab therapy. Patients & methods: Of adult patients enrolled in the RAINBOW study, 39 had received prior trastuzumab therapy. Of these, 20 patients were treated with ramucirumab plus paclitaxel and 19 patients with placebo plus paclitaxel within the RAINBOW trial. Results: Overall survival was longer with ramucirumab plus paclitaxel (11.4 months; 95% CI: 7.0-17.9) versus placebo plus paclitaxel (7.0 months; 95% CI: 3.4-14.6), hazard ratio: 0.68 (0.33-1.41); p = 0.30. Longer progression-free survival, higher objective response were observed in ramucirumab combination group. Conclusion: Ramucirumab plus paclitaxel demonstrated efficacy benefits with manageable safety profile in a subgroup of patients pretreated with trastuzumab. Clinical trial registration number: NCT01170663.

Original languageEnglish
Pages (from-to)2723-2731
Number of pages9
JournalFuture Oncology
Volume15
Issue number23
DOIs
StatePublished - Aug 2019

Funding

FundersFunder number
Eli Lilly and Company

    Keywords

    • HER-2 inhibitor
    • VEGFR-2 inhibitor
    • gastric cancer
    • prior trastuzumab
    • ramucirumab plus paclitaxel
    • targeted therapy

    Fingerprint

    Dive into the research topics of 'Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: Subgroup analysis from RAINBOW study'. Together they form a unique fingerprint.

    Cite this